FDA Accepts MOGENRY Application for Severe Retinitis Pigmentosa
FDA accepted and filed Nanoscope Therapeutics’ biologics license application for MOGENRY, or sonpiretigene isteparvovec, in retinitis pigmentosa with severe vision loss. The one-time intravitreal optogenetic therapy is intended to work across causal genotypes by…
